首页> 美国卫生研究院文献>BMC Cancer >γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

【2h】

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

机译：γH2AX和Chk1磷酸化作为Chk1抑制剂-化学疗法联合治疗的预测药效生物标志物

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundChk1 inhibitors are currently in clinical trials in combination with a range of cytotoxic agents and have the potential to potentiate the clinical activity of a large number of standard of care chemotherapeutic agents. Utilizing pharmacodynamic biomarkers to optimize drug dose and scheduling in these trials could greatly enhance the likelihood of clinical success.

机译：背景技术Chk1抑制剂目前正在与多种细胞毒剂联合进行临床试验，并且有可能增强多种标准护理化学治疗剂的临床活性。在这些试验中使用药效学生物标记物优化药物剂量和时间表可以极大地提高临床成功的可能性。

著录项

期刊名称 BMC Cancer
作者
Rebecca Rawlinson; Andrew J Massey;
展开▼
作者单位

展开▼
年(卷),期 2014(14),-1
年度 2014
页码 483
总页数 13
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Chk1 DNA damage Biomarker Combination therapy;

机译：Chk1;DNA损伤;生物标志物;联合治疗;

相似文献

外文文献
中文文献
专利

1. γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments [J] . Rebecca Rawlinson, Andrew J Massey BMC Cancer . 2014,第1期

机译：γH2AX和Chk1磷酸化作为Chk1抑制剂-化学疗法联合治疗的预测药效生物标志物
2. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. [J] . Parsels LA, Qian Y, Tanska DM, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第11期

机译：评估chk1磷酸化作为chk1抑制的药效生物标志物。
3. Enhanced H2AX Phosphorylation, DNA Replication Fork Arrest, and Cell Death in the Absence of Chk1 [J] . Mary E. Gagou, Pedro Zuazua-Villar, Mark Meuth Molecular biology of the cell . 2010,第5期

机译：增强的H2AX磷酸化，DNA复制叉逮捕和缺少Chk1的细胞死亡
4. Development of pharmacodynamic biomarkers for Duchenne muscular dystrophy using exon skipping treatment and mdx mouse model. [C] . Haeri Seol, Meng H Han, Aiping Zhang, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：外显子跳跃治疗和MDX小鼠模型的Duchenne肌营养不良药物动力学生物标志物的发展。
5. Multiscale Pharmacodynamic Studies of Combination Gemcitabine and Trabectedin for the Treatment of Pancreatic Cancer. [D] . Miao, Xin. 2017

机译：吉西他滨联合曲贝汀联合治疗胰腺癌的多尺度药效学研究。
6. Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition [O] . Leslie A. Parsels, Yushen Qian, Daria M. Tanska, -1

机译：评估CHK1磷酸化作为CHK1抑制的药效生物标志物
7. γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments [O] . Rebecca Rawlinson, Andrew J Massey 2014

机译：γH2AX和Chk1磷酸化作为Chk1抑制剂-化学疗法联合治疗的预测药效生物标志物

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

摘要

著录项

相似文献

相关主题

期刊订阅